Next Article in Journal
Screening of Potential Xanthine Oxidase Inhibitors in Gnaphalium hypoleucum DC. by Immobilized Metal Affinity Chromatography and Ultrafiltration-Ultra Performance Liquid Chromatography-Mass Spectrometry
Next Article in Special Issue
Therapeutic Effects of Phytochemicals and Medicinal Herbs on Chemotherapy-Induced Peripheral Neuropathy
Previous Article in Journal
Chemical Constituents from Flueggea virosa and the Structural Revision of Dehydrochebulic Acid Trimethyl Ester
Previous Article in Special Issue
Extracts from Traditional Chinese Medicinal Plants Inhibit Acetylcholinesterase, a Known Alzheimer’s Disease Target
Open AccessReview

Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence?

Department of Physiology and Pharmacology, Sapienza—University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
*
Author to whom correspondence should be addressed.
Molecules 2016, 21(9), 1243; https://doi.org/10.3390/molecules21091243
Received: 26 July 2016 / Accepted: 12 September 2016 / Published: 17 September 2016
A growing body of in vitro and in vivo evidences shows a possible role of polyphenols in counteracting neurodegeneration: curcumin and resveratrol are attractive substances in this regard. In fact, epidemiological studies highlight a neuroprotective effect of turmeric (rhizome of Curcuma longa L.), the main source of curcumin. Moreover, the consumption of red wine, the main source of resveratrol, has been related to a lower risk of developing dementia. In this review, we analyzed the published clinical trials investigating curcumin and resveratrol in the prevention or treatment of cognitive disorders. The ongoing studies were also described, in order to give an overview of the current search on this topic. The results of published trials (five for curcumin, six for resveratrol) are disappointing and do not allow to draw conclusions about the therapeutic or neuroprotective potential of curcumin and resveratrol. These compounds, being capable of interfering with several processes implicated in the early stages of dementia, could be useful in preventing or in slowing down the pathology. To this aim, an early diagnosis using peripheral biomarkers becomes necessary. Furthermore, the potential preventive activity of curcumin and resveratrol should be evaluated in long-term exposure clinical trials, using preparations with high bioavailability and that are well standardized. View Full-Text
Keywords: polyphenols; curcumin; turmeric; resveratrol; grape wine; dementia; Alzheimer; cognitive disorders; clinical trials polyphenols; curcumin; turmeric; resveratrol; grape wine; dementia; Alzheimer; cognitive disorders; clinical trials
Show Figures

Figure 1

MDPI and ACS Style

Mazzanti, G.; Di Giacomo, S. Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence? Molecules 2016, 21, 1243. https://doi.org/10.3390/molecules21091243

AMA Style

Mazzanti G, Di Giacomo S. Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence? Molecules. 2016; 21(9):1243. https://doi.org/10.3390/molecules21091243

Chicago/Turabian Style

Mazzanti, Gabriela; Di Giacomo, Silvia. 2016. "Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence?" Molecules 21, no. 9: 1243. https://doi.org/10.3390/molecules21091243

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop